Financial Analysis

Contingencies The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (PRP) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Companys responsibility is established and when the cost can be reasonably estimated. The Company has accrued $10.8 million and $14.2 million as of December 28, 2025 and December 29, 2024, respecti vely, in accrued expenses and other current liabilities, which represents its managements estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. The Companys environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to con …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

Debt The Companys debt consisted of the following: December 28, 2025 Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ $ $ (2,857) $ (2,857) 1.900% Senior Unsecured Notes due in 2028 (2028 Notes) 500,000 (148) (1,791) 498,061 3.3% Senior Unsecured Notes due in 2029 (2029 Notes) 850,000 (1,169) (3,235) 845,596 2.55% Senior Unsecured Notes due in March 2031 (March 2031 Notes) 400,000 (75) (1,952) 397,973 2.250% Senior Unsecured Notes due in September 2031 (September 2031 Notes) 500,000 (919) (2,641) 496,440 3.625% Senior Unsecured Notes due in 2051 (2051 Notes) 400,000 (3) (3,974) 396,023 Total Long-Term Debt 2,650,000 (2,314) (16,450) 2,631,236 Current Portion of Long-Term Debt: 500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (2026 Notes) 589,450 (343) (279) 588,828 Total Current Portion of Long-Term Debt 589,450 (343) (279) 588,828 Total Debt $ 3,239,450 $ (2,657) $ (16,729) $ 3,220,064 December 29, 2024 Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ $ $ (1,208) $ (1,208) 2026 Notes 521,700 (834) (780) 520,086 2028 Notes 500,000 (200) (2,408) 497,392 2029 Notes 850,000 (1,448) (4,010) 844,542 March 2031 Notes 400,000 (88) (2,294) 397,618 September 2031 Notes 500,000 (1,065) (3,059) 495,876 2051 Notes 400,000 (4) ( …

DebtDisclosureTextBlock · excerpt; the full note is in the filing

In the following tables, revenue is disaggregated by primary geographical market and major good and service lines. Reportable Segments For the fiscal year ended December 28, 2025 December 29, 2024 December 31, 2023 Life Sciences Diagnostics Total Life Sciences Diagnostics Total Life Sciences Diagnostics Total (In thousands) Primary geographical markets Americas $ 750,857 $ 505,104 $ 1,255,961 $ 745,206 $ 477,881 $ 1,223,087 $ 759,782 $ 455,831 $ 1,215,613 Europe 343,507 481,471 824,978 315,173 427,441 742,614 344,713 402,310 747,023 Asia 336,740 438,372 775,112 338,222 451,103 789,325 353,697 434,238 787,935 $ 1,431,104 $ 1,424,947 $ 2,856,051 $ 1,398,601 $ 1,356,425 $ 2,755,026 $ 1,458,192 $ 1,292,379 $ 2,750,571 Major goods/service lines Life Sciences Solutions $ 1,194,728 $ $ 1,194,728 $ 1,197,802 $ $ 1,197,802 $ 1,279,903 $ $ 1,279,903 Software 236,376 236,376 200,799 200,799 178,289 178,289 Immunodiagnostics 869,908 869,908 828,627 828,627 787,394 787,394 Reproductive health 555,039 555,039 527,798 527,798 504,985 504,985 $ 1,431,104 $ 1,424,947 $ 2,856,051 $ 1,398,601 $ 1,356,425 $ 2,755,026 $ 1,458,192 $ 1,292,379 $ 2,750,571 …

DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing

Stock Plans Stock-Based Compensation: The Companys 2019 Incentive Plan (the 2019 Plan) authorizes the issuance of stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards and cash awards as part of the Companys compensation programs. The 2019 Plan replaced the Companys 2009 Incentive Plan (the 2009 Plan). Upon shareholder approval of the 2019 Plan, 6.25 million shares of the Companys common stock, as well as shares of the Companys common stock previously granted under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price subject to a contractual repurchase right, became available for grant under the 2019 Plan. Awards granted under the 2009 Plan prior to its expiration remain outstanding. As part of the Companys compensation programs, the Company also offers shares of its common stock under its Employee Stock Purchase Plan. The following table summarizes total pre-tax compensation expense recognized related to the Companys stock options, restricted stock, restricted stock units, performance restricted stock units and stock grants, included in the Companys consolidated statements of operations: December 28, 2025 December 29, 2024 December 31, 2023 (In thousands) Cost of product and service revenue $ 2,149 $ 2,495 $ 4,224 Research and development expenses 1,577 3,863 5,276 Selling, general and administrative expenses 19,121 31,451 31 …

DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock · excerpt; the full note is in the filing

Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities, accounts receivable and notes receivable. The Company believes it had no significant concentrations of credit risk as of December 28, 2025. The Companys financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Companys currency risk, and acqu isition and divestiture related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial assets or liabilitys classification within the hierarchy is determined based on the lowest level input that is significant t …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

Goodwill and Intangible Assets, Net The changes in the carrying amount of goodwill for fiscal years 2025 and 2024 are as follows: Life Sciences Diagnostics Consolidated (In thousands) Balance at December 31, 2023 $ 4,587,938 $ 1,945,612 $ 6,533,550 Foreign currency translation (46,471) (23,460) (69,931) Balance at December 29, 2024 4,541,467 1,922,152 6,463,619 Foreign currency translation 105,495 44,379 149,874 Other 98,000 (98,000) Balance at December 28, 2025 $ 4,744,962 $ 1,868,531 $ 6,613,493 Amortizable intangible asset balances at December 28, 2025 and December 29, 2024 were as follows: December 28, 2025 December 29, 2024 (In thousands) Patents $ 27,592 $ 27,808 Less: Accumulated amortization (26,524) (26,293) Net patents 1,068 1,515 Trade names and trademarks 150,103 142,588 Less: Accumulated amortization (102,234) (87,824) Net trade names and trademarks 47,869 54,764 Licenses 27,561 27,164 Less: Accumulated amortization (19,849) (17,855) Net licenses 7,712 9,309 Core technology 1,624,925 1,561,831 Less: Accumulated amortization (921,325) (735,532) Net core technology 703,600 826,299 Customer relationships 2,870,384 2,807,909 Less: Accumulated amortization (1,283,630) (1,058,875) Net customer relationships 1,586,754 1,749,034 Net amortizable intangible assets $ 2,347,003 $ 2,640,921 Total amortization expense related to amortizable intangible assets was $335.6 million in fiscal year 2025, $359.4 million in fiscal year 2024 and $365.1 million in fiscal year 2023. Estim …

GoodwillAndIntangibleAssetsDisclosureTextBlock · excerpt; the full note is in the filing

Employee Benefit Plans Savings Plan: The Company has a 401(k) Savings Plan for the benefit of all qualified U.S. employees, with such employees receiving matching contributions in the amount equal to 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits. Savings plan expense was $13.8 million in fiscal year 2025, $13.3 million in fiscal year 2024, and $15.0 million in fiscal year 2023. Pension Plans: The Company has a defined benefit pension plan covering certain U.S. employees and non-U.S. pension plans for certain non-U.S. employees. The principal U.S. defined benefit pension plan is closed to new hires and plan benefits have been frozen. The plans provide benefits that are based on an employees years of service and compensation near retirement. In December 2024, the Company entered into an annuity purchase agreement to irrevocably transfer a portion of the U.S. pension benefit obligation to a third-party insurance company. The annuity purchase price was $94.1 million and was funded from U.S. pension plan assets. The resulting settlement of the U.S. pension plan was not material and is included in the actuarial gains and losses recognized during fiscal year 2024. In January 2025, the Company executed a sale of its United Kingdom (UK) pension plan to a third party as part of a multi-year buy-out plan. Following satisfaction of all obligations in the buy-out agreement, excess plan assets of $2.7 million, net of taxes, reverted to t …

PensionAndOtherPostretirementBenefitsDisclosureTextBlock · excerpt; the full note is in the filing

Restructuring and Other Costs Restructuring and other costs in fiscal year 2025 primarily included charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. In fiscal year 2025, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the Companys workforce. Restructuring and other costs in fiscal years 2024 and 2023 primarily included charges for workforce reductions and facility consolidations, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. Severance actions associated with facility consolidations and cost reduction initiatives were not material to the Companys overall workforce in both fiscal years. Restructuring and other costs, included in the selling, general and administrative expenses in the consolidated statements of operations, by segment are as follows: December 28, 2025 December 29, 2024 December 31, 2023 (In thousands) Life Sciences $ 15,552 $ 4,532 $ 6,203 Diagnostics 39,337 12,539 15,465 Corporate 1,043 383 4,933 $ 55,932 $ 17,454 $ 26,601 The following table summarizes the changes in the Companys accrued restructuring balance for fiscal year 202 5. The changes in …

RestructuringAndRelatedActivitiesDisclosureTextBlock · excerpt; the full note is in the filing

Revenue For arrangements with multiple performance obligations, the Company accounts for individual products and services separately if they are distinct - i.e., if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated to each performance obligation in an arrangement based on relative stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products, extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis. The Company sells products and services predominantly through its direct sales force, and the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty). In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical exp …

RevenueFromContractWithCustomerTextBlock · excerpt; the full note is in the filing

Segment and Geographic Area Information The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The CODM of the Company is the Chief Executive Officer (CEO). The CEO evaluates the performance of its operating segments based on revenue and operating income as adjusted for certain items. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1. Effective at the beginning of fiscal year 2025, the Company implemented changes to its operating model. The majority of the Company s Applied Genomics business, previously reported as part of the Diagnostics segment, has been integrated into a newly formed Life Sciences Solutions business, encompassing all Life Sciences reagents and consumables, instruments and services, as well as technology and licensing, which is reported as part of the Life Sciences segment. Beginning in fiscal year 2025, the Life Sciences segment consists of Life Sciences Solutions and Software, while the Diagnostics segment consists of Immunodiagnostics and Reproductive Health. The effect of the change is not significant. Prior period financial information has been reclassified to reflect this new segment composition for consistent comparison. The Company has included the expenses for its corporate headquarters, such as legal, t …

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

Stockholders Equity Comprehensive Income: The components of accumulated other comprehensive (loss) income consisted of the following: Foreign Currency Translation Adjustment, net of tax Unrecognized Prior Service Costs, net of tax Unrealized (Losses) Gains on Securities, net of tax Accumulated Other Comprehensive (Loss) Income (In thousands) Balance, January 1, 2023 $ (446,664) $ (798) $ (35) $ (447,497) Current year change 80,172 (181) 79,991 Reclassification to retained earnings 90,814 90,814 Balance, December 31, 2023 (275,678) (798) (216) (276,692) Current year change (119,260) (153) (119,413) Balance, December 29, 2024 (394,938) (798) (369) (396,105) Current year change 173,876 94 173,970 Balance, December 28, 2025 $ (221,062) $ (798) $ (275) $ (222,135) The unrealized foreign exchange (gains) losses, net of income taxes, on intercompany debt for which repayment is not anticipated in the foreseeable future that was recorded in AOCI for the fiscal years 2025, 2024 and 2023 were $(165.3) million, $(0.9) million and $11.3 million, respectively. Income taxes related to foreign currency translation adjustments recognized in AOCI during fiscal year 2025 were $59.5 million. Income taxes related to foreign currency translation adjustments recognized in AOCI during fiscal years 2024 and 2023 were not material. Stock Repurchases: On October 24, 2024, the Board authorized the Company to repurchase shares of common stock for an aggregate amount up to $1.0 billion under a stock repur …

StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing

Subsequent Events Subsequent to fiscal year 2025, the Company completed its acquisition of Advanced Chemistry Development Inc. (ACD/Labs) for $72 million in cash paid at the closing and up to $8 million in contingent consideration to be paid in cash based on the achievement of certain revenue metrics through 2028. AC D/Labs is based in Toronto, Canada, has approximately 200 employees, and is a provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. ACD/Labs will be recognized in the Life Sciences segment. …

SubsequentEventsTextBlock · excerpt; the full note is in the filing

Contingencies The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (PRP) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Companys responsibility is established and when the cost can be reasonably estimated. The Company has accrued $11.1 million and $14.2 million as of September 28, 2025 and December 29, 2024, respectively, which represents its managements estimate of the cost of the remediation of known environmental matters and does not include any potential liability for related personal injury or property damage claims. These amounts were included in accrued expenses and other current liabilities. The Companys environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other signi …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

Debt The Companys debt consisted of the following: September 28, 2025 Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ $ $ (3,035) $ (3,035) 1.900% Senior Unsecured Notes due in 2028 500,000 (160) (1,929) 497,911 3.3% Senior Unsecured Notes due in 2029 850,000 (1,224) (3,390) 845,386 2.55% Senior Unsecured Notes due in March 2031 400,000 (77) (2,018) 397,905 2.250% Senior Unsecured Notes due in September 2031 500,000 (950) (2,730) 496,320 3.625% Senior Unsecured Notes due in 2051 400,000 (3) (3,966) 396,031 Other Debt Facilities, non-current 175 175 Total Long-Term Debt $ 2,650,175 $ (2,414) $ (17,068) $ 2,630,693 Current Portion of Long-term Debt: 500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (2026 Notes) 584,550 (492) (404) 583,654 Other Debt Facilities, current 190 190 Total Current Portion of Long-Term Debt 584,740 (492) (404) 583,844 Total $ 3,234,915 $ (2,906) $ (17,472) $ 3,214,537 The Company entered into a senior unsecured revolving credit facility in 2021 (the 2021 Senior Unsecured Revolving Credit Facility) with a five-year term and a borrowing capacity of $1.5 billion available through August 24, 2026. On January 7, 2025 , the 2021 Senior Unsecured Revolving Credit Facility was replaced with a new senior unsecured revolving credit facility with a five-year term and a borrowing capacity of $1.5 billion available through Januar …

DebtDisclosureTextBlock · excerpt; the full note is in the filing

Disaggregated revenue by primary geographical markets and major goods and service lines are as follows: Reportable Segments Three Months Ended September 28, 2025 September 29, 2024 Life Sciences Diagnostics Total Life Sciences Diagnostics Total (In thousands) Primary geographical markets Americas $ 178,087 $ 129,190 $ 307,277 $ 185,476 $ 116,849 $ 302,325 Europe 83,332 119,065 202,397 75,115 106,923 182,038 Asia 81,403 107,872 189,275 78,209 121,477 199,686 $ 342,822 $ 356,127 $ 698,949 $ 338,800 $ 345,249 $ 684,049 Major goods/service lines Life Sciences Solutions $ 290,541 $ $ 290,541 $ 295,455 $ $ 295,455 Software 52,281 52,281 43,345 43,345 Immunodiagnostics 212,739 212,739 211,566 211,566 Reproductive health 143,388 143,388 133,683 133,683 $ 342,822 $ 356,127 $ 698,949 $ 338,800 $ 345,249 $ 684,049 Reportable Segments Nine Months Ended September 28, 2025 September 29, 2024 Life Sciences Diagnostics Total Life Sciences Diagnostics Total (In thousands) Primary geographical markets Americas $ 559,437 $ 376,049 $ 935,486 $ 551,843 $ 352,619 $ 904,462 Europe 243,652 344,169 587,821 227,123 318,065 545,188 Asia 246,026 314,662 560,688 244,873 331,131 576,004 $ 1,049,115 $ 1,034,880 $ 2,083,995 $ 1,023,839 $ 1,001,815 $ 2,025,654 Major goods/service lines Life Sciences Solutions $ 875,046 $ $ 875,046 $ 884,849 $ $ 884,849 Software 174,069 174,069 138,990 138,990 Immunodiagnostics 629,119 629,119 613,479 613,479 Reproductive health 405,761 405,761 388,336 388,336 $ 1,049,115 $ 1 …

DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing

Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, accounts receivable and notes receivable. The Company believes it had no significant concentrations of credit risk as of September 28, 2025. The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the nine months ended September 28, 2025. The Companys financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Companys currency risk, and acqu isition and divestiture related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms an …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

Goodwill and Intangible Assets, Net The Company tests goodwill at least annually for possible impairment. The Company completes the annual testing of impairment for goodwill on the later of November 1 or the first day of its eleventh fiscal month of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. The Company performed its annual impairment testing for its reporting units for fiscal year 2024 as of November 1, 2024. There were no impairments measured in the periods presented. While the Company believes that its estimates of current value are reasonable, if actual results differ from the estimates and judgments used, including such items as future cash flows and the volatility inherent in markets which the Company serves, impairment charges against the carrying value of those assets could be required in the future. The changes in the carrying amount of goodwill for the nine months ended September 28, 2025 …

GoodwillAndIntangibleAssetsDisclosureTextBlock · excerpt; the full note is in the filing

Revenue Disaggregation of revenue Disaggregated revenue by primary geographical markets and major goods and service lines are as follows: Reportable Segments Three Months Ended September 28, 2025 September 29, 2024 Life Sciences Diagnostics Total Life Sciences Diagnostics Total (In thousands) Primary geographical markets Americas $ 178,087 $ 129,190 $ 307,277 $ 185,476 $ 116,849 $ 302,325 Europe 83,332 119,065 202,397 75,115 106,923 182,038 Asia 81,403 107,872 189,275 78,209 121,477 199,686 $ 342,822 $ 356,127 $ 698,949 $ 338,800 $ 345,249 $ 684,049 Major goods/service lines Life Sciences Solutions $ 290,541 $ $ 290,541 $ 295,455 $ $ 295,455 Software 52,281 52,281 43,345 43,345 Immunodiagnostics 212,739 212,739 211,566 211,566 Reproductive health 143,388 143,388 133,683 133,683 $ 342,822 $ 356,127 $ 698,949 $ 338,800 $ 345,249 $ 684,049 Reportable Segments Nine Months Ended September 28, 2025 September 29, 2024 Life Sciences Diagnostics Total Life Sciences Diagnostics Total (In thousands) Primary geographical markets Americas $ 559,437 $ 376,049 $ 935,486 $ 551,843 $ 352,619 $ 904,462 Europe 243,652 344,169 587,821 227,123 318,065 545,188 Asia 246,026 314,662 560,688 244,873 331,131 576,004 $ 1,049,115 $ 1,034,880 $ 2,083,995 $ 1,023,839 $ 1,001,815 $ 2,025,654 Major goods/service lines Life Sciences Solutions $ 875,046 $ $ 875,046 $ 884,849 $ $ 884,849 Software 174,069 174,069 138,990 138,990 Immunodiagnostics 629,119 629,119 613,479 613,479 Reproductive health 405,761 405,7 …

RevenueFromContractWithCustomerTextBlock · excerpt; the full note is in the filing

Segment Information The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company s chief operating decision maker (CODM) is the Chief Executive Officer. The CODM evaluates the performance of the Companys operating segments based on revenue and operating income adjusted for certain items. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1, Nature of Operations and Accounting Policies, to the audited consolidated financial statements in the 2024 Form 10-K. Effective at the beginning of fiscal year 2025, the Company implemented changes to its operating model. The majority of the Company s Applied Genomics business, previously reported as part of the Diagnostics segment, has been integrated into a newly formed Life Sciences Solutions business, encompassing all Life Sciences reagents and consumables, instruments and services, as well as technology and licensing, which is reported as part of the Life Sciences segment. Beginning in fiscal year 2025, the Life Sciences segment consists of Life Sciences Solutions and Software, while the Diagnostics segment consists of Immunodiagnostics and Reproductive Health. The effect of the change is not significant. Prior period financial information has been reclassified to reflect this new segmen …

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

Stockholders Equity Comprehensive Income: The components of accumulated other comprehensive loss consisted of the following: September 28, 2025 December 29, 2024 (In thousands) Foreign currency translation adjustments, net of income taxes $ (178,659) $ (394,938) Unrecognized prior service costs, net of income taxes (798) (798) Unrealized net losses on marketable securities, net of income taxes (348) (369) Accumulated other comprehensive loss $ (179,805) $ (396,105) The unrealized foreign exchange losses (gains) on intercompany debt for which repayment is not anticipated in the foreseeable future that was recorded in accumulated other comprehensive income (AOCI) were $22.6 million and $2.8 million for the three months ended September 28, 2025 and September 29, 2024, respectively, and $(206.1) million and $1.5 million for the nine months ended September 28, 2025 and September 29, 2024, respectively. Stock Repurchases: On October 24, 2024 , the Companys Board of Directors (the Board) authorized the Company to repurchase shares of common stock for an aggregate amount up to $1.0 billion under a stock repurchase program (the Repurchase Program). The Repurchase Program was set to expire on October 23, 2026 unless terminated earlier by the Board and could have been suspended or discontinued at any time. D uring the three months ended September 28, 2025 , the Company repurchased 2,322,206 shares of common stock under the Repurchase Program for an aggregate cost of $204.9 million. Duri …

StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing